Intergroupe Francophone de Cancerologie Thoracique   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Paris France (1999)

Organization Overview

First Clinical Trial
2001
NCT00198354
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Intergroupe Francophone de Cancerologie Thoracique | Intergroupe Francophone de Cancerologie Thoracique (IFCT)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma, Bronchiolo-Alveolar (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Meningeal Carcinomatosis (Phase 2)

Mesothelioma (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Neuroendocrine Tumors (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 36
  • # of Trial APIs: 30